Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes

Korell, Felix; Berger, Trisha R.; Maus, Marcela V.

doi:10.1016/j.medj.2022.05.001

Cited by 24 publications

(13 citation statements)

References 207 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The function of CAR T-cells is closely associated with endogenous immune cells in the circulation system and tumor cells, immune cells and stromal cells in the TME. The complex cellular interactions involved in the function of CAR T-cells are critical to understanding the mechanism of action of CAR T-cells [ 82 ]. A study performed scRNA-seq on CAR T-cell products and PBMCs from plasma cell leukemia (PCL) patients after receiving CAR T-cell treatment.…”

Section: Deciphering and Advancing Car T-cell Biologymentioning

confidence: 99%

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

Huang

Wang

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular patterns at unprecedented resolution, have greatly advanced our understanding of immunology and oncology. In this review, we summarize the recent applications of single-cell sequencing technologies in CAR T-cell therapy, including the biological characteristics, the latest mechanisms of clinical response and adverse events, promising strategies that contribute to the development of CAR T-cell therapy and CAR target selection. Generally, we propose a multi-omics research mode to guide potential future research on CAR T-cell therapy.

show abstract

Section: Deciphering and Advancing Car T-cell Biologymentioning

confidence: 99%

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

Huang

Wang

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…CAR-T cells have four major components: an extracellular or antigen-recognition domain (usually single-chain variable fragments (scFv)), a hinge, a transmembrane, and an intracellular signaling domain (most commonly CD3ζ). Unlike conventional T cells, CARs function independently of the major histocompatibility complex (MHC), allowing for the recognition of a more extensive range of tumor-associated antigens [ 6 •]. CAR design has evolved over four generations to increase the efficacy of the therapy.…”

Section: Introductionmentioning

confidence: 99%

CAR-T Therapies in Solid Tumors: Opportunities and Challenges

et al. 2023

View full text Add to dashboard Cite

Purpose of Review This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles. In addition, this review will examine therapies that are in development for pediatric solid tumors. Recent Findings The similar success of CAR-T cell treatment for hematological malignancies has not been observed in solid tumors because of the hostile tumor microenvironment and tumor heterogeneity. Most strategies developed to combat these limitations emphasize combinatorial techniques that still require further testing. Preliminary results of multiple clinical trials, including GD2- and HER2-CAR-T cells, are encouraging but must be reproduced and validated on a larger scale. Summary CAR-T cell application in solid tumors remains challenging, and most research is in development. Several clinical trials are ongoing for pediatric solid tumors. Early results are promising but demonstrate the need for CAR-T cell modification to prevent tumor recurrence.

show abstract

“…Chimeric antigen receptors (CAR) empower T cells to recognize and kill target cells through genetic engineering. This therapy has proven effective for patients with relapsed or refractory B and plasma cell malignancies, leading to six CAR T‐cell products approved by the FDA—four targeting CD19 and two targeting B‐cell maturation antigen (BCMA) [1]. The first to be approved (tisagenlecleucel [tisa‐cel], followed quickly by axicabtagene ciloleucel [axi‐cel], in 2017) were the first gene therapies approved in the United States, marking a new era of cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

Four challenges to CAR T cells breaking the glass ceiling

et al. 2023

Self Cite

View full text Add to dashboard Cite

Cell‐based therapies using chimeric antigen receptor T cells (CAR T) have had dramatic efficacy in the clinic and can even mediate curative responses in patients with hematologic malignancies. As living drugs, engineered cells can still be detected in some patients even years after the original infusion. The excitement around the cell therapy field continues to expand as recent reports have shown that CAR T cells can induce remission in patients with autoimmune disease. While these promising advances in the field garner hope for wide‐spread utility of CAR T therapies across diseases, several roadblocks exist that currently limit the access and efficacy of this therapy in the clinic. Herein, we will discuss four major obstacles that the CAR T field faces, including toxicity, identifying tumor‐specific antigens, improving function in solid tumors, and reducing manufacturing complexity and cost. CAR T cells have potential for a multitude of diseases, but these glass ceilings will need to be broken in order to improve clinical responses and make this potentially life‐saving therapy accessible to a larger patient population.

show abstract

Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes

Cited by 24 publications

References 207 publications

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

CAR-T Therapies in Solid Tumors: Opportunities and Challenges

Four challenges to CAR T cells breaking the glass ceiling

Contact Info

Product

Resources

About